Pancreatic Cancer is the 3rd 

Leading Cause of Cancer Death


There is an unmet need in oncology for new biomarkers that can be used as early detection tools and for guiding treatment. Reccan Diagnostics has a strong scientific expertise in identifying protein targets specific for clinical application using state-of-the-art mass spectrometry and validation by orthogonal platforms like tissue microarray, immunohistochemistry and ELISA. Proteomic studies includes various technical disciplines, where Reccan Diagnostics has cutting edge capability and experience. In particular, we have have adopted the use of Parallel Reaction Monitoring Mass Spectrometry (PRM-MS) on which a high throughput platform has been built for rapid screening of samples in a simultaneously cost efficient, quantitative and extremely accurate way.


Clinical studies & sample repository

Disease treatments will in the future be entirely dependent on precision diagnostics that will enable diagnosis at an earlier stage and identification of responders to treatment. Reccan Diagnostics has access to high quality clinical biobank material (blood and tissue) combined with extensive register data for patients and a cutting edge mass spectrometric technology, which provides optimal possibilities to develop diagnostic assays. This provides the opportunity to develop a variety of products for various indications:

  • screening

  • diagnosis

  • staging and prognosis

  • probe for diagnostic imaging

  • prediction of treatment response (companion diagnostics)



The primary focus of Reccan Diagnostics is to develop a protein-based in vitro assay for early diagnosis of pancreatic cancer using a small amount of blood. Additional tissue tests are also developed to aid in molecular stratification of pancreatic cancer, of importance for prognostication and selection of optimal treatment. The intellectual property of Reccan Diagnostics includes several patents.